Compare Innovative Industrial Properties Inc (IIPR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Recursion Pharmaceuticals Inc — how do they compare? Innovative Industrial Properties Inc trades at $51.76 (market cap $1.43B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| IIPR | RXRX | |
|---|---|---|
Market Cap | $1.43B | $2.14B |
Volume | 394,222 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $6.79 |
52-Week Low | $44.58 | $2.84 |
Typical Hold Time | 86 Days | 23 Days |
Enterprise Value | $1.96B | $1.66B |
Dividend Yield | 14.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.87, up 1.25% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings, beating in Q2 but missing in Q1, with revenue declining to $266 million in 2025. Valuation ratios appear attractive with a P/E of 11.75 and P/B of 0.83, while the company maintains a high net income margin of 52.27%. Recent news highlights a $245 million mezzanine loan commitment and a declared $1.90 dividend.
The outlook is cautious due to declining revenue and negative net cash flow in 2025, offset by strong profitability and a discounted valuation. Risks include tenant defaults and dividend sustainability concerns, but analyst consensus suggests upside with a $84.67 price target. The stock presents a high-yield opportunity with significant re-rating potential if operational challenges are managed.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
